uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)
uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract...
uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)
Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition
uBriGene Biosciences Inc. closes 150 million CNY (20 million USD) Series C+ round
uBriGene Biosciences completes several hundred million yuan Series C round funding
Correcting visual impairment: VGR-R01 project IND application accepted by Center for Drug Evaluation
Assisted Clinical Application of Gene Therapy for Hemophilia B of Vitalgen Accepted by NMPA
Assisted Clinical Application of Gene Therapy in Ophthalmology of Innostellar Accepted by NMPA